This was a key question in clinical research, especially considering that obese individuals often have lower circulating ghrelin levels, which might suggest a different response to ghrelin agonists
Ozempic was originally found to regulate blood sugar and is approved as a treatment for type 2 diabetes, while Wegovy was subsequently approved for weight loss and management
The risk increases significantly when Ozempic is used in combination with insulin or sulfonylureas
As a result, BPC-157 is not FDA-approved for the treatment of joint or tendon injuries, and its use remains experimental or off-label
STEP 1 (published in NEJM 2021) demonstrated that participants receiving semaglutide 2.4 mg experienced mean reductions in total cholesterol of approximately 5-7%, LDL-C reductions of 5-8%, and triglyceride reductions of 12-15% from baseline
These medications include insulin injections and sulfonylurea drugs, such as Glucotrol (glipizide), DiaBeta (glyburide), Amaryl (glimepiride), and others